Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TAL1
REST API REST API
Homo sapiens
TAL1 is differentially expressed in 254 experiments: 107 organism parts: bone marrow, liver, ... (105 more);, 188 disease states: normal, acute myeloid leukemia, ... (186 more);, 98 cell types 192 cell lines 34 compound treatments and 79 other conditions.
Synonyms SCL, TCL5, bHLHa17
Orthologs Tal1 (Mus musculus)   Tal1 (Rattus norvegicus)   TAL1 (Bos taurus)   tal1 (Danio rerio)   HLH3B (Drosophila melanogaster)   tal1 (Xenopus laevis)   TAL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, neuron differentiation, positive regulation of cell division, DNA binding, protein binding, regulation of transcription, DNA-dependent, histone deacetylase complex, nuclear chromatin, regulation of cell proliferation, protein complex, transcription, DNA-dependent, locomotory behavior, histone deacetylase binding, hemopoiesis, positive regulation of mitotic cell cycle, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, positive regulation of protein complex assembly, nucleus, protein heterodimerization activity, transcription factor complex, cell fate commitment, chromatin binding, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, enzyme binding, positive regulation of transcription, DNA-dependent, embryonic hemopoiesis, positive regulation of erythrocyte differentiation, regulation of myeloid cell differentiation, definitive hemopoiesis, E-box binding, erythrocyte differentiation, platelet formation, megakaryocyte differentiation, spinal cord association neuron differentiation, hemopoietic stem cell differentiation, generation of neurons, astrocyte fate commitment, erythrocyte maturation, myeloid cell differentiation, hemangioblast cell differentiation, sequence-specific DNA binding transcription factor activity, regulation of stem cell maintenance, Lsd1/2 complex, transcription regulatory region sequence-specific DNA binding, sequence-specific DNA binding RNA polymerase II transcription factor activity, basophil differentiation, RNA polymerase II transcription factor binding, positive regulation of chromatin assembly or disassembly, transcription regulatory region DNA binding, regulation of mast cell differentiation, RNA polymerase II distal enhancer sequence-specific DNA binding, megakaryocyte development
InterPro Term HLH_DNA-bd
UniProt Accession Q9UE36, P17542, E7EVM2
Search EB-eye ENSG00000162367
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, E-MEXP-1269, ... (29 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
Jurkat
3
E-MTAB-62, E-GEOD-1880, E-MEXP-2197
K562
3
E-MTAB-37, E-GEOD-24147, E-GEOD-96
MDA468
2
E-MEXP-440, E-MTAB-62
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
186 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (46 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-3998, E-GEOD-96, E-GEOD-19240
memory B cell
2
E-MEXP-2360, E-TABM-702
2
2
E-TABM-145, E-TABM-130
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (61 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-16363, E-GEOD-20602, E-GEOD-20295, E-GEOD-16728
chronic myelogenous leukemia
4
E-MTAB-37, E-MTAB-62, E-GEOD-96, E-GEOD-5550
lung adenocarcinoma
4
E-MEXP-231, E-GEOD-2514, E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-GEOD-7307
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
182 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5824, E-GEOD-4748, E-GEOD-15811, ... (23 experiments)

Factor Value U/D Experiments
none
2
5
E-MEXP-1230, E-GEOD-5824, E-GEOD-2706, E-GEOD-7400, E-GEOD-412, ... (7 experiments)
glutamine
2
E-MEXP-941, E-MEXP-1335
control
2
E-GEOD-3284, E-GEOD-7664
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
immunoglobulin E
1
E-GEOD-3982
28 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-TABM-127, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-TABM-740, E-MEXP-2069, E-GEOD-3606, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-MEXP-1412, E-GEOD-1657, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.334 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM